本文關鍵詞： 嵌合型抗原受體T細胞 卵巢癌　出處：《免疫學雜志》2017年02期 　論文類型：期刊論文

【摘要】：嵌合型抗原受體T細胞(CAR-T)是通過基因工程方法表達特定靶抗原抗體單鏈可變區(qū)(sc Fv)的T細胞。隨著CAR-T在血液系統(tǒng)腫瘤治療療效的確定,實體腫瘤的研究者們也開始試用CAR-T治療。然而,CAR-T在實體腫瘤中的治療療效遠遠低于預期。本文對CAR-T的設計原理做了簡單的總結并討論各種形式CAR-T及其優(yōu)缺點。在此基礎上,我們也討論了CAR-T在實體腫瘤中療效低的原因。最后,我們以卵巢癌為例對CAR-T研究存在的挑戰(zhàn)做了前瞻性的預測。
[Abstract]:Chimeric antigen receptor T cells (CAR-T) are T cells expressing single chain variable region (sc FV) of specific target antigen antibodies by genetic engineering. The researchers of solid tumor have also begun to try CAR-T treatment. However, the therapeutic effect of CAR-T in solid tumor is much lower than expected. This paper briefly summarizes the design principle of CAR-T and discusses the various forms of CAR-T and its advantages and disadvantages. We also discussed the reasons for the low efficacy of CAR-T in solid tumors. Finally, we used ovarian cancer as an example to predict the challenges of CAR-T research.
【作者單位】： 同濟大學附屬第十人民醫(yī)院婦產(chǎn)科;
【分類號】：R737.31
，

本文編號：1535035